Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2013 - 2026)

Rigel Pharmaceuticals has reported Other Operating Expenses for 13 years, with the latest figure at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 4.47% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (down 5.77% YoY), and the FY2025 full-year result was $19.6 million, up 5.22% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $4.6 million, down from $6.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $14.5 million in Q4 2022, with the low at $121000.0 in Q1 2022.
• Average Other Operating Expenses over 5 years is $3.9 million, with a median of $3.8 million recorded in 2023.
• Peak annual rise in Other Operating Expenses reached 707.44% in 2023, while the deepest fall reached 73.91% in 2023.
• Tracing RIGL's Other Operating Expenses over 5 years: stood at $14.5 million in 2022, then plunged by 73.91% to $3.8 million in 2023, then jumped by 52.74% to $5.8 million in 2024, then climbed by 2.87% to $6.0 million in 2025, then decreased by 22.65% to $4.6 million in 2026.
• The last three Other Operating Expenses figures came in at $4.6 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.

Peer Comparison